奥卡西平口服混悬液对特发性癫痫患儿免疫功能的影响  

Therapeutic efficiency of Oxcarbazepine Oral Suspension on immune functions of idiopathic epilepsy children

作　　者：孙素真[1] 刘芳[1] 施荣富[1] 王智华[2] 张文杰[2] 唐红霞[1] 杨华芳[1] 

机构地区：[1]河北省儿童医院神经内科,石家庄050031 [2]河北省人民医院老年病研究室,石家庄050051

出　　处：《第三军医大学学报》2011年第9期964-966,共3页Journal of Third Military Medical University

摘　　要：目的观察奥卡西平口服混悬液单药治疗对特发性癫痫患儿细胞免疫及体液免疫功能的影响。方法采用定期门诊随访,用药前、用药后3个月、6个月分别采集25例特发性癫痫患儿(癫痫组)及21例健康体检儿童(正常对照组)空腹静脉血以全自动生化分析仪采用免疫比浊法检测血清免疫球蛋白IgG、IgA、IgM及流式细胞分析仪检测CD3、CD4、CD8及ICAM-I。结果癫痫患儿用药前IgA[(0.75±0.42)g/L]、IgG[(7.74±2.65)g/L]、ICAM-1(38.07±12.87)、CD8(19.61±5.52)含量升高,CD3(40.27±9.66)、CD4(20.63±8.97)下降,与正常对照组比较差异有显著性(P<0.05),而IgM[(1.10±0.50)g/L]与正常对照组比较差异无显著性(P>0.05);用药3个月后IgA[(0.29±0.18)g/L]、IgG[(6.66±1.84)g/L]、CD8(16.27±6.53)下降,CD3(50.55±13.35)升高,与用药前比较差异有显著性(P<0.05),与正常对照组比较差异无显著性(P>0.05);用药6个月后IgA[(0.25±0.13)g/L]、IgG[(6.07±1.46)g/L]、CD8(14.22±4.76)、ICAM-1(29.83±10.84)下降,CD4(26.58±9.76)升高,与用药前比较差异有显著性(P<0.05),与正常对照组比较差异无显著性(P>0.05);IgM与正常对照组及用药前比较差异均无显著性(P>0.05)。用药3个月与6个月各指标比较差异无显著性(P>0.05)。结论特发性癫痫患儿用药前即存在细胞免疫及体液免疫功能的紊乱,奥卡西平口服混悬液在控制癫痫发作的同时,可改善癫痫患儿的免疫状态。Objective To identify the efficiency of Oxcarbazepine Oral Suspension monotherapy on the cellular immunity and humoral immunity of children with idiopathic epilepsy.Methods A total of 25 children with idiopathic epilepsy（epilepsy group） who were outpatients from March to October 2009 and 21 gender and age matched normal children（control group） were subjected in this study.Before and in 3 and 6 months after treatment,their venous blood was collected respectively on an empty stomach.An automatic biochemical analyzer（olympusAu640） was employed to detect serum immunoglobulin IgG,IgA and IgM through immune turbidimetry,while the contents of CD3,CD4,CD8 and intercellular adhesion molecule-1（ICAM-1） were measured with flow cytometry.Results Before the oral administration of Oxcarbazepine Oral Suspension,the serum levels of IgA（0.75±0.42 g/L）,IgG（7.74±2.65 g/L）,ICAM-1（38.07±12.87）,and CD8（19.61±5.52） in the epilepsy children were significantly higher,while those of CD3（40.27±9.66） and CD4（20.63±8.97） were significantly lower than those of the normal control group（P0.05）,whereas there was no significant difference in serum level of IgM between epilepsy children（1.10±0.50 g/L） and normal control group（P0.05）.After the 3-month treatment,the serum levels of IgA（0.29±0.18 g/L）,IgG（6.66±1.84 g/L）,and CD8（16.27±6.53） were decreased,and that of CD3（50.55±13.35） were increased.After the 6-month treatment,the serum levels of IgA（0.25±0.13 g/L）,IgG（6.07±1.46 g/L）,CD8（14.22±4.76）,and ICAM-1（29.83±10.84） were decreased,and that of CD4（26.58±9.76） was increased,with significant differences when compared with those before treatment（P0.05）.These values had no significant difference compared with those of normal control group（P0.05）,but there were significant differences when compared with those of normal control（P0.05）.There was no significant difference in serum level of IgM among the epilepsy group before or after treatm

关 键 词：特发性癫痫 儿童 奥卡西平口服混悬液 细胞免疫 体液免疫 

分 类 号：R749.17[医药卫生—神经病学与精神病学] R971.6[医药卫生—临床医学]